Eizo Keeps Getting it Right

Eizo released a new monitor, the RadiForce MX217, for the healthcare industry and it got us thinking about what a neat company it is.

Eizo won a Scientific and Technical Award by the Academy of Motion Picture Arts and Sciences for its ColorEdge CG Series monitors. In the same vein, its color calibration technology for its monitors in healthcare are peerless.

The company recently announced the release of the RadiForce MX217, a 21.3-inch 2 megapixel (1200 x 1600 pixels) color monitor for displaying patient charts and reviewing diagnostic imaging in hospital and clinic environments. Displays in the medical profession have pretty strict guidelines for how displays should be tested and calibrated for gray scale images, DICOM Part 14, but increasingly, color images are also being used in diagnostic scenarios. If you’re a true display junkie then there’s nothing better than diving deep into medical imaging because it is about the only segment of the industry where display quality is a life or death issue. Well, maybe Hollywood, too.

The medical industry products sit next to products that go into design, film and TV production, traffic control, and even Pachinko machines in Japan. Eizo is Japan’s only local display maker, has a pretty amazing reputation over the course of many decades, and is servicing some of the most exacting users of displays in some very exclusive niche market segments. That makes it a Formula 1 company in the display business. So, why hasn’t a bigger brand, someone more mainstream, picked up the company? It’s an ideal target for an acquisition because it gives you access to the most demanding standards for displays, and all that knowledge and goodwill can trickle down your product line.

But, there’s also something else, Eizo is really tight with its customers meaning, it has great customer service and understands them. That level of engagement is going to be essential to any company making technology transitions in the coming years, as everyone in the display industry will have to, and as new market opportunities open up in niche markets.